Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott’s Next-Generation Spinal Cord Stimulator Gets FDA Nod

Executive Summary

The newly approved Proclaim Plus system allows physicians to treat as many as six independent pain sites and choose the lowest-possible effective dose for each site.

You may also be interested in...



Abbott Launches NeuroSphere Virtual Clinic For Remote Neurostim Programming

The US FDA approved Abbott's system that allows physicians to communicate with patients and remotely program their neuromodulation device.

Minute Insight: Smith + Nephew Expands VR-based Surgical Training

Smith + Nephew is expanding its suite of simulation technologies to train surgeons on new techniques before they enter the operating room.

BTIG Analyst Zooms Into Alcon’s Revamp Into ‘Building A Pharma Company Inside A Device Company’

In his recent report on Alcon, BTIG analyst Ryan Zimmerman estimated that its pharmaceutical portfolio could generate close to $900m in fiscal year 2022.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT145746

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel